Products
Pre-made Praluzatamab Ravtansine benchmark antibody (Whole mAb ADC, anti-ALCAM therapeutic antibody, Anti-CD166/MEMD Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-964
Pre-made Praluzatamab Ravtansine benchmark antibody (Whole mAb ADC, anti-ALCAM therapeutic antibody, Anti-CD166/MEMD Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-964-1mg | 1mg | Inquiry | ||
| GMP-Bios-INN-964-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-964-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-964-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Praluzatamab Ravtansine Biosimilar, Whole Mab Adc, Anti-Alcam Antibody: Anti-CD166/MEMD therapeutic antibody Drug Conjugate |
| INN Name | Praluzatamab Ravtansine |
| Target | ALCAM |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | CytomX Therapeutics Inc. (South San Francisco CA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
<